Meeting
2022 ASCO Genitourinary Cancers Symposium
Comprehensive genomic profiling of urine DNA for urothelial carcinoma detection and risk prediction.
Authors
Keyan Salari
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Keyan Salari , Jason J. Lee , Vincent T. Bicocca , Vincent Caruso , Brian C. Mazzarella , Kevin G. Phillips , Trevor G. Levin , Adam S. Feldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 450)
DOI
10.1200/JCO.2022.40.6_suppl.450
Abstract #
450
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
First Author: Neeta DSouza
Poster
2021 Genitourinary Cancers Symposium
Is there a role for urine cytology following BCG therapy for non-muscle-invasive bladder cancer (NMIBC)?
First Author: Sarah Prattley
Poster
2019 Genitourinary Cancers Symposium
Percent genome alteration and outcomes after radical prostatectomy in African American men.
First Author: Farzana A Faisal
Poster
2018 ASCO Annual Meeting
Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs.
First Author: Ilija Aleksic